Edge Therapeutics (EDGE) Given Daily News Impact Rating of 0.26
News articles about Edge Therapeutics (NASDAQ:EDGE) have trended positive recently, according to Accern. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Edge Therapeutics earned a coverage optimism score of 0.26 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 50.3025507637012 out of 100, meaning that recent news coverage is somewhat likely to have an impact on the stock’s share price in the immediate future.
These are some of the media stories that may have effected Accern Sentiment’s analysis:
- Morphotek To Present Its Proprietary RESPECT™ Antibody-Drug Conj – KAIT Jonesboro, AR – Region 8 News, weather, sports (kait8.com)
- Candidiasis – Pipeline Review, H2 2017 Market Report; Launched via MarketResearchReports.com (sbwire.com)
- Edge Therapeutics Inc (EDGE) CEO Sells $24,800.00 in Stock (americanbankingnews.com)
- Edge Therapeutics Inc (EDGE) Insider Sells $73,950.00 in Stock (americanbankingnews.com)
- Anti-Inflammatory Therapeutics Market Estimated to Flourish by 2013 – 2019 (sbwire.com)
Shares of Edge Therapeutics (EDGE) traded up $0.02 during mid-day trading on Friday, reaching $9.25. 38,072 shares of the company’s stock traded hands, compared to its average volume of 45,525. The company has a debt-to-equity ratio of 0.20, a quick ratio of 8.34 and a current ratio of 8.34. Edge Therapeutics has a 52-week low of $7.30 and a 52-week high of $13.50.
A number of brokerages recently weighed in on EDGE. Zacks Investment Research upgraded shares of Edge Therapeutics from a “sell” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Monday, November 6th. BidaskClub downgraded shares of Edge Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, August 14th.
In other Edge Therapeutics news, insider Albert N. Marchio II sold 3,361 shares of the firm’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $10.00, for a total transaction of $33,610.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Brian A. Leuthner sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $10.96, for a total transaction of $82,200.00. The disclosure for this sale can be found here. Insiders have sold a total of 35,861 shares of company stock worth $378,035 over the last 90 days. Corporate insiders own 36.19% of the company’s stock.
WARNING: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/12/09/edge-therapeutics-edge-given-daily-news-impact-rating-of-0-26.html.
Edge Therapeutics Company Profile
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
Receive News & Stock Ratings for Edge Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc and related stocks with our FREE daily email newsletter.